Loading organizations...
§ Private Profile · Suzhou, Jiangsu, China
Medical device company developing AI-powered diagnostic and therapeutic solutions for cardiovascular diseases, serving hospitals.
Based in Suzhou, China, AccuPulse develops medical devices for cardiac electrophysiology, focusing on pulsed electric field ablation and 3D ECG calibration systems to diagnose and treat arrhythmias. The company operates with an estimated 21 to 50 employees and maintains a product pipeline of nearly ten items, including AI-powered mapping systems and intracardiac ultrasound catheters. AccuPulse has secured approximately $45 million in total funding across multiple equity rounds to support clinical trials, while generating an estimated $2.3 million in annual revenue. The medical technology developer is backed by notable institutional investors, including Shenzhen Qianhai Capital, Shanghai Biomedical Industry Equity Investment Fund, and Yuanbio Ventures. Its executive team includes industry veterans with prior experience at major medical corporations such as Biosense Webster and Acutus Medical. AccuPulse was founded in November 2020 by chief executive officer Jie Yin.
AccuPulse has raised $1.5B across 4 funding rounds.
AccuPulse has raised $1.5B in total across 4 funding rounds.
AccuPulse has raised $1.5B across 4 funding rounds. Most recently, it raised $1.5B Other Equity in March 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 13, 2026 | $1.5B Venture Round | 中金资本 | 元璟资本 | Announced |
| Jun 17, 2024 | $6.9M Venture Round | Deng Jianxin | — | Announced |
| Feb 7, 2024 | $27.8M Series A | Shanghai Biopharmaceutical Fund, Shengshi Investment Management | — | Announced |
| May 27, 2022 | $10M Series A | Shenzhen Qianhai Capital | Shanghai Biopharmaceutical Fund | Announced |
AccuPulse has raised $1.5B in total across 4 funding rounds.
AccuPulse's investors include 中金资本, 元璟资本, Deng Jianxin, Shanghai Biopharmaceutical Fund, Shengshi Investment Management, Shenzhen Qianhai Capital.